leadf
logo-loader
viewMedlab Clinical Ltd
(
ASX:MDC
)

Medlab Clinical proceeding to stage II for cannabis cancer trial

The company will now proceed with stage II of the human clinical trial.

cannabis leaf and green tablets
Stage I findings showed that NanaBis™ is safe indications confirm it helps with pain reduction

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Medlab has received formal approval from the appropriate authority to proceed to stage II of the human cancer trial. 

Stage II of the clinical trial will focus on further safety but also tolerance and dose escalation.

READ: Medlab Clinical receives vital licence to export cannabis

Key data findings from stage I include that NanaBis™ is safe, is effective up to nine hours in a single dose, and early indications confirm it helps with pain reduction.

Medlab’s CEO Dr Sean Hall said: “These results confirm and validate our original hypothesis and offer a true alternative to current pain medications.

“I’m looking forward to data from stage II.

“Although pain measurement was not a key part of stage I, the early results of pain reduction while being administered NanaBis™ was very encouraging.”

In stage II, Medlab will continue with cancer patients but this time with unmanaged pain.

READ: Medlab Clinical receives positive early research results for NanoCelle™

In September, Medlab received preliminary results from research reviewing its patented delivery platform, NanoCelle™.

NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth and it is being tested using Medlab’s cannabis-based medicines, NanaBis™ and NanaBidial™.

The research concluded positively that molecules of the medicines, NanaBis™ and NanaBidial™ showed a consistent uniform pattern in nanoparticle form.

The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.

Quick facts: Medlab Clinical Ltd

Follow
ASX:MDC

Price: 0.16 AUD

Market Cap: $54.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle...

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue generating partnering opportunities for its NanoCelle®...

on 24/6/21

2 min read